BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October

Day

• 1
• 2
• 3
• 5
• 6
• 7
• 8
• 9
• 10
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 24
• 26
• 27
• 28
• 29
• 30
• 31

• Press Releases

  Ratio Therapeutics Closes $70 Million Series C Financing to Advance Clinical Development of Targeted Radiotherapeutics Pipeline and Expand Manufacturing Infrastructure

  July 31, 2026

   · 

  2 min read
• Press Releases

  AbbVie Reports Second-Quarter 2026 Financial Results

  July 31, 2026

   · 

  28 min read
• Press Releases

  Hemostemix Closes Second Tranche of Private Placement and Obtains Extension to August 14, 2026

  July 31, 2026

   · 

  8 min read
• Press Releases

  BioMark Diagnostics Endorses Global Call for Equitable Access to Early Screening on 2026 World Lung Cancer Day

  Anchored in the 2026 global campaign’s core mission of early detection, equitable access to screening, and compassionate patient support, BioMark advances its multi-marker liquid biopsy to ensure no patient is left behind.

  July 31, 2026

   · 

  4 min read
• Press Releases

  Scientific Paper Detailing Preclinical Studies of Narmafotinib in Pancreatic Cancer Now Online

  July 31, 2026

   · 

  3 min read
• 

  Regulatory

  Capricor CEO won’t rule out legal action against FDA after negative adcomm

  After an FDA advisory committee voted 9-3 on Wednesday against recommending Capricor Therapeutics’ Duchenne muscular dystrophy cardiomyopathy drug for approval, stakeholders allege an “ulterior motive” and “biased intentions.”

  July 31, 2026

   · 

  6 min read

   · 

  Heather McKenzie
• 

  Earnings

  Moderna maintains 10% growth target despite Phase 3 norovirus miss

  Moderna’s norovirus vaccine failed in a Phase 3 trial, but the company still has faith in an ambitious revenue growth target thanks to ex-U.S. vaccine sales and a unanimous FDA adcomm win for mFLUSIVA.

  July 31, 2026

   · 

  4 min read

   · 

  Gabrielle Masson
• 

  Earnings

  AbbVie shares pressured as Q2 I&I beat falls below investor expectations

  AbbVie investors’ sky-high expectations led to a 4% share decline on Friday as the company reported more modest consensus beats than expected.

  July 31, 2026

   · 

  3 min read

   · 

  Annalee Armstrong
• 

  Cardiovascular disease

  Novo’s IL-6 inhibitor fails in cardiovascular Phase 3, plunging shares more than 9%

  Novo Nordisk’s IL-6 inhibitor ziltivekimab failed to reduce the risk of cardiovascular events in the late-stage trial, dashing hopes for an edge in the hyper-competitive cardiometabolic space.

  July 31, 2026

   · 

  2 min read

   · 

  Michael Gibney
• 

  Deals

  Lilly and Resilience invest $750M in diabetes and obesity drug device supply

  The investment will expand Resilience’s U.S. capacity to make the KwikPen device Eli Lilly uses to deliver its injectable diabetes and obesity medicines.

  July 31, 2026

   · 

  1 min read

   · 

  Nick Paul Taylor